产品说明书

Gefapixant

Print
Chemical Structure| 1015787-98-0 同义名 : MK-7264;AF-219
CAS号 : 1015787-98-0
货号 : A503454
分子式 : C14H19N5O4S
纯度 : 98%
分子量 : 353.397
MDL号 : MFCD24539325
存储条件:

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 4 mg/mL(11.32 mM),配合低频超声,并调节pH至5-6,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Gefapixant is an orally effective antagonist of P2X3R, with an IC50 value of approximately 30 nM against recombinant homotrimeric hP2X3, and an IC50 value ranging from 100-250 nM against the heterotrimeric hP2X2/3 receptor. Gefapixant does not inhibit receptors containing non-P2X3 subunits, including recombinant homotrimers hP2X1, hP2X2, hP2X4, rP2X5, and hP2X7. Gefapixant is useful for research into chronic cough and knee osteoarthritis[1][2][3].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02612623 Refractory Chronic Cough Phase 2 Completed - United States, California ... 展开 >> Afferent Investigative Site Mission Viejo, California, United States Afferent Investigative Site San Jose, California, United States United States, Colorado Afferent Investigative Site Colorado Springs, Colorado, United States United States, Florida Afferent Investigative Site Largo, Florida, United States United States, North Carolina Afferent Investigative Site Charlotte, North Carolina, United States United States, Oklahoma Afferent Investigative Site Tulsa, Oklahoma, United States United States, Texas Afferent Investigative Site Dallas, Texas, United States Afferent Investigative Site San Antonio, Texas, United States United States, Washington Afferent Investigative Site Bellevue, Washington, United States United States, Wisconsin Afferent Investigative Site Greenfield, Wisconsin, United States 收起 <<
NCT01554579 Osteoarthritis of the Knee Phase 2 Completed - -
NCT01554579 - Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.83mL

0.57mL

0.28mL

14.15mL

2.83mL

1.41mL

28.30mL

5.66mL

2.83mL

参考文献

[1]Anthony P. Ford, et al. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013; 7: 267.

[2]Ford AP, In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal. 2012 Feb;8(Suppl 1):3-26.

[3]Martin Nguyen A, et al. Validation of a visual analog scale for assessing cough severity in patients with chronic cough. Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049743.